WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > GFBiochemicals
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Industrial Impact
Enveric Biosciences, Inc | July 14, 2022
Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property advances achieved during the first half of 2022. “The first half of 2022 was foundationally successful for Enveric. We validated and executed on the corporate premise that we can deploy Psy...
Cell and Gene Therapy
Tachyon Therapeutics Inc. | August 25, 2022
Tachyon Therapeutics, Inc. a private biotechnology company developing transformative cancer therapies against novel targets, today announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application to develop TACH101 for the treatment of advanced solid tumors. "The approval of this IND marks a significant milestone for the Company, as TACH101 will be the first KDM4 inhibitor to enter clinical stage. ...
Sirona Biochem Corp. | November 24, 2022
Sirona Biochem Corp. announces that, subsequent to the LOI, Sirona and Wanbang Biopharmaceuticals have signed an expanded, international partnership agreement to collaborate on licencing Sirona’s SGLT2 inhibitor, TFC-039, as a pharmaceutical treatment in both animal and human health. The agreement adds human health to the partnership as a result of new licencing opportunities currently in due diligence. Wanbang and Sirona initially signed a licensing agreement for TFC-039, w...
Express Healthcare | April 02, 2020
The investment in MedGenome will seek to capitalise on favourable dynamics in both domestic, international markets for genetic diagnostics. MedGenome recently announced an investment of $55m led by LeapFrog Investments. Existing investors Sofina and Sequoia also participated in the round. Sam Santhosh, CEO and Founder, MedGenome said, “Genomics and personalised medicine are the future of healthcare, but emerging markets remain significantly under-penetrated. As the largest player in India ...
Video
Cell and Gene Therapy, Medical
Whitepaper
Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE